143 related articles for article (PubMed ID: 31662533)
21. [Not Available].
Gladieff L; Lyonnet DS; Lortholary A; Leary A; Genestie C; Ray-Coquard I
Bull Cancer; 2017 May; 104 Suppl 1():S16-S23. PubMed ID: 28625311
[TBL] [Abstract][Full Text] [Related]
22. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.
Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES
BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688
[TBL] [Abstract][Full Text] [Related]
23. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
24. Olaparib for the treatment of BRCA-mutated advanced ovarian cancer.
Munroe M; Kolesar J
Am J Health Syst Pharm; 2016 Jul; 73(14):1037-41. PubMed ID: 27385701
[TBL] [Abstract][Full Text] [Related]
25. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
Moore KN; Monk BJ
Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
[TBL] [Abstract][Full Text] [Related]
26. [Olaparib in ovarian cancer with BRCA mutation].
Pujade-Lauraine É; Combe P
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S82-4. PubMed ID: 26118881
[TBL] [Abstract][Full Text] [Related]
27. Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations.
Moore KN; Birrer MJ
Oncologist; 2018 Jun; 23(6):697-703. PubMed ID: 29593098
[TBL] [Abstract][Full Text] [Related]
28. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.
Kortmann U; McAlpine JN; Xue H; Guan J; Ha G; Tully S; Shafait S; Lau A; Cranston AN; O'Connor MJ; Huntsman DG; Wang Y; Gilks CB
Clin Cancer Res; 2011 Feb; 17(4):783-91. PubMed ID: 21097693
[TBL] [Abstract][Full Text] [Related]
29. Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer.
LaFargue CJ; Tewari KS
Recent Pat Biotechnol; 2016; 9(2):86-101. PubMed ID: 26961668
[TBL] [Abstract][Full Text] [Related]
30. Incorporating PARP-inhibitors into clinical routine: A tailored treatment strategy to tackle ovarian cancer.
De Jaeghere E; Vandecasteele K; Claes K; Makar A; Tummers P; Cocquyt V; Denys H
Acta Clin Belg; 2017 Feb; 72(1):6-11. PubMed ID: 27267353
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
Lee CK; Scott C; Lindeman GJ; Hamilton A; Lieschke E; Gibbs E; Asher R; Badger H; Paterson R; Macnab L; Kwan EM; Francis PA; Boyle F; Friedlander M
Br J Cancer; 2019 Feb; 120(3):279-285. PubMed ID: 30655615
[TBL] [Abstract][Full Text] [Related]
32. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu JF; Matulonis UA
Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
[TBL] [Abstract][Full Text] [Related]
33. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
34. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
35. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
36. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract][Full Text] [Related]
37. Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.
Stewart J; George A; Banerjee S
Expert Rev Anticancer Ther; 2018 Oct; 18(10):947-958. PubMed ID: 30092674
[TBL] [Abstract][Full Text] [Related]
38. Spotlight on olaparib in the treatment of BRCA-mutated ovarian cancer: design, development and place in therapy.
Lorusso D; Tripodi E; Maltese G; Lepori S; Sabatucci I; Bogani G; Raspagliesi F
Drug Des Devel Ther; 2018; 12():1501-1509. PubMed ID: 29881257
[TBL] [Abstract][Full Text] [Related]
39. PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.
Smith HJ; Walters Haygood CL; Arend RC; Leath CA; Straughn JM
Gynecol Oncol; 2015 Oct; 139(1):59-62. PubMed ID: 26303225
[TBL] [Abstract][Full Text] [Related]
40. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer.
Eetezadi S; Evans JC; Shen YT; De Souza R; Piquette-Miller M; Allen C
Mol Pharm; 2018 Feb; 15(2):472-485. PubMed ID: 29283581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]